Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.71 USD | -0.88% | -2.78% | +115.69% |
Sales 2024 * | 96.88M 8.08B | Sales 2025 * | 117M 9.72B | Capitalization | 644M 53.69B |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.92B | Net income 2025 * | -22M -1.83B | EV / Sales 2024 * | 5.52 x |
Net cash position 2024 * | 109M 9.07B | Net cash position 2025 * | 130M 10.8B | EV / Sales 2025 * | 4.41 x |
P/E ratio 2024 * |
-28.6
x | P/E ratio 2025 * |
-34.2
x | Employees | 100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.46% |
Latest transcript on Y-mAbs Therapeutics, Inc.
1 day | -0.88% | ||
1 week | -2.78% | ||
Current month | -9.53% | ||
1 month | -6.31% | ||
3 months | +30.52% | ||
6 months | +172.91% | ||
Current year | +115.69% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Gad
FOU | Founder | 54 | 01/15/01 |
Michael Rossi
CEO | Chief Executive Officer | 53 | 06/11 |
Bo Kruse
DFI | Director of Finance/CFO | 52 | 01/16/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Gill
BRD | Director/Board Member | 69 | 01/17/01 |
Director/Board Member | 54 | 01/15/01 | |
James Healy
CHM | Chairman | 58 | 01/17/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 509 M€ | -.--% | ||
0.01% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 14.71 | -0.88% | 189,796 |
25/24/25 | 14.84 | -2.94% | 365,385 |
24/24/24 | 15.29 | -0.33% | 158,222 |
23/24/23 | 15.34 | +1.19% | 513,319 |
22/24/22 | 15.16 | +0.20% | 472,662 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+115.69% | 644M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- YMAB Stock